Pacific Biosciences of California Inc (NASDAQ: PACB) closed the day trading at $3.35 up 0.60% from the previous closing price of $3.33. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 4725883 shares were traded.
Ratios:
For a better understanding of PACB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.81. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Meline David W bought 40,000 shares for $4.40 per share. The transaction valued at 176,160 led to the insider holds 40,000 shares of the business.
HENRY CHRISTIAN O sold 14,177 shares of PACB for $69,056 on Mar 04 ’24. The insider now owns 2,596,670 shares after completing the transaction at $4.87 per share. On Mar 04 ’24, another insider, Van Oene Mark, who serves as the insider of the company, sold 9,186 shares for $4.87 each. As a result, the insider received 44,745 and left with 1,668,826 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 894.96M and an Enterprise Value of 1.20B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.48 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 5.97 whereas that against EBITDA is -4.32.
Stock Price History:
Over the past 52 weeks, PACB has reached a high of $14.55, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is 5.0732, while the 200-Day Moving Average is calculated to be 8.5595.
Shares Statistics:
Over the past 3-months, PACB traded about 8.86M shares per day on average, while over the past 10 days, PACB traded about 6.29M shares per day. A total of 267.74M shares are outstanding, with a floating share count of 251.64M. Insiders hold about 6.09% of the company’s shares, while institutions hold 98.31% stake in the company. Shares short for PACB as of Mar 15, 2024 were 45.57M with a Short Ratio of 5.14, compared to 40.38M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.01% and a Short% of Float of 18.85%.
Earnings Estimates
Current recommendations for the stock of the company come from 12 analysts. On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.3, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.24 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.93 and -$1.1 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$0.86, with 12 analysts recommending between -$0.68 and -$1.1.
Revenue Estimates
10 analysts predict $50.39M in revenue for the current quarter. It ranges from a high estimate of $52.76M to a low estimate of $48M. As of the current estimate, Pacific Biosciences of California Inc’s year-ago sales were $34.38M, an estimated increase of 46.60% from the year-ago figure.
A total of 13 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $244.7M, while the lowest revenue estimate was $229.5M, resulting in an average revenue estimate of $238.82M. In the same quarter a year ago, actual revenue was $200.52M, up 19.10% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $347.59M in the next fiscal year. The high estimate is $395M and the low estimate is $299M. The average revenue growth estimate for next year is up 45.50% from the average revenue estimate for this year.
